Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.81 USD | -0.71% | +1.55% | -30.87% |
Financials (USD)
Sales 2024 * | 510M | Sales 2025 * | 642M | Capitalization | 2.9B |
---|---|---|---|---|---|
Net income 2024 * | -65M | Net income 2025 * | 65M | EV / Sales 2024 * | 6.04 x |
Net Debt 2024 * | 182M | Net Debt 2025 * | 84.17M | EV / Sales 2025 * | 4.65 x |
P/E ratio 2024 * |
-45.5
x | P/E ratio 2025 * |
46.7
x | Employees | 517 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics, Inc.
1 day | -0.71% | ||
1 week | +1.55% | ||
Current month | +0.10% | ||
1 month | -1.80% | ||
3 months | -23.48% | ||
6 months | -10.98% | ||
Current year | -30.87% |
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Simon Harford
DFI | Director of Finance/CFO | 63 | 23-08-20 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 22-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 06-03-31 |
Lynn Bleil
BRD | Director/Board Member | 60 | 18-09-10 |
Burke Whitman
BRD | Director/Board Member | 68 | 19-06-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.91% | 14 M€ | -5.07% | ||
0.32% | 0 M€ | 0.00% | - | |
0.29% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 9.8 | -0.81% | 2,904,632 |
24-05-30 | 9.88 | +5.56% | 2,203,727 |
24-05-29 | 9.36 | -2.30% | 1,644,807 |
24-05-28 | 9.58 | -0.83% | 1,757,598 |
24-05-24 | 9.66 | +2.01% | 3,165,807 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.87% | 2.91B | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+0.04% | 12.16B | |
+25.12% | 12.21B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- FOLD Stock